2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network

Kazuomi Kario, Sungha Park, Yook Chin Chia, Apichard Sukonthasarn, Yuda Turana, Jinho Shin, Chen Huan Chen, Peera Buranakitjaroen, Romeo Divinagracia, Jennifer Nailes, Satoshi Hoshide, Saulat Siddique, Jorge Sison, Arieska Ann Soenarta, Guru Prasad Sogunuru, Jam Chin Tay, Boon Wee Teo, Yu Qing Zhang, Huynh Van Minh, Naoko TomitaniTomoyuki Kabutoya, Narsingh Verma, Tzung Dau Wang, Ji Guang Wang

Research output: Contribution to journalReview articlepeer-review

24 Citations (Scopus)

Abstract

Hypertension professionals from Asia have been meeting together for the last decade to discuss how to improve the management of hypertension. Based on these education and research activities, the Hypertension, brain, cardiovascular and renal Outcome Prevention and Evidence in Asia (HOPE Asia) Network was officially established in June 2018 and includes experts from 12 countries/regions across Asia. Among the numerous research and review papers published by members of the HOPE Asia Network since 2017, publications in three key areas provide important guidance on the management of hypertension in Asia. This article highlights key consensus documents, which relate to the Asian characteristics of hypertension, home blood pressure monitoring (HBPM), and ambulatory blood pressure monitoring (ABPM). Hypertension and hypertension-related diseases are common in Asia, and their characteristics differ from those in other populations. It is essential that these are taken into consideration to provide the best opportunity for achieving “perfect 24-hour blood pressure control”, guided by out-of-office (home and ambulatory) blood pressure monitoring. These region-specific consensus documents should contribute to optimizing individual and population-based hypertension management strategies in Asian country. In addition, the HOPE Asia Network model provides a good example of the local interpretation, modification, and dissemination of international best practice to benefit specific populations.

Original languageEnglish
Pages (from-to)351-362
Number of pages12
JournalJournal of Clinical Hypertension
Volume22
Issue number3
DOIs
Publication statusPublished - 2020 Mar 1

Bibliographical note

Funding Information:
We appreciate two key mentors, Dr Michael A Weber, Dr Daniel T Lackland?and Dr Aletta E Schutte, for their heartfelt advice and support on our HOPE Asia Network activity. We also thank Pfizer, Daichi Sankyo, Omron Healthcare, A&D and Fukuda Denshi Co. Ltd. for the grants to support HOPE Asia Network activities. Medical writing assistance was provided by Nicola Ryan, independent medical writer.

Funding Information:
K Kario received research grants from Omron Healthcare, A&D, and Fukuda Denshi Co. Ltd. S Park has received research grants and honoraria from Pfizer. S Siddique has received honoraria from Bayer, Novartis, Pfizer, ICI, and Servier; and travel, accommodation, and conference registration support from Atco Pharmaceutical, Highnoon Laboratories, Horizon Pharma, ICI, Pfizer and CCL. YC Chia has received honoraria and sponsorship to attend conferences and CME seminars from Abbott, Bayer, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Novartis, Orient Europharma, Pfizer, and Sanofi; and a research grant from Pfizer. J Shin has received honoraria and sponsorship to attend seminars from Daiichi Sankyo, Takeda, Menarini, MSD, Bristol‐Myers Squibb, and Sanofi. CH Chen has served as an advisor or consultant for Novartis Pharmaceuticals Corporation; has served as a speaker or a member of a speakers bureau for AstraZeneca; Pfizer Inc; Bayer AG; Bristol‐Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Novartis Pharmaceuticals Corporation; SERVIER; Merck & Co., Inc; Sanofi; TAKEDA Pharmaceuticals International; and has received grants for clinical research from Microlife Co., Ltd. R Divinagracia has received honoraria as a member of speaker's bureaus for Bayer, Novartis, and Pfizer. J Sison has received honoraria from Pfizer, AstraZeneca, Boehringer Ingelheim and Novartis. GP Sogunuru has received a research grant related to hypertension monitoring and treatment from Pfizer. JC Tay has received advisory board and consultant honoraria from Pfizer. BW TEO has received honoraria for lectures and consulting fees from Astellas, AstraZeneca, Boehringer Ingelheim, Servier, MSD, and Novartis. TD Wang has served as an advisor for Medtronic and Omron Healthcare; has served as a speaker for Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Novartis, Pfizer, and Sanofi; and has received research grants/support from Abbott, Medtronic, and Novartis. JG Wang has received research grants from Bayer, Merck Sharp & Dohme, Pfizer, and Phillips; and lecture and consulting fees from Bayer, HanHui, Merck, Omron, Salubris, Servier and Takeda. Y Zhang has received research grants from Bayer, Novartis, and Shuanghe; and lecture fees from Bayer, Daiichi Sankyo, Novartis, Pfizer, Sanofi, Servier, and Takeda. All other authors report no potential conflicts of interest in relation to this article.

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of '2020 Consensus summary on the management of hypertension in Asia from the HOPE Asia Network'. Together they form a unique fingerprint.

Cite this